Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 7/2018

01-07-2018 | Observational Research

Decreased CD22 expression and intracellular signaling aberrations in B cells of patients with systemic sclerosis

Authors: Konstantinos Melissaropoulos, Stamatis-Nick Liossis

Published in: Rheumatology International | Issue 7/2018

Login to get access

Abstract

The objective of the study was to explore the phenotype and intracellular signaling events of B cells in patients with systemic sclerosis (SSc). Peripheral blood B cell surface markers CD19 and CD22 were evaluated by flow cytometry in 23 patients with SSc and seven healthy individuals. Levels of intracellular kinases Lyn, Syk and P-Y 348 Syk along with phosphatase SHP-1 were examined with Western immunoblotting in selected patients. P-Y 822 CD22 was subsequently evaluated flow cytometrically in antigen receptor stimulated B cells. A statistically significant decrease in CD22 B cell surface expression was found in the diffuse subset of patients (median CD22 MFI ± SD was 5.90 ± 2.35 vs 10.20 ± 1.88 for patients vs healthy controls respectively; p = 0.021), while no statistically significant change was found regarding CD19. CD22 underexpression was more pronounced when interstitial lung disease (ILD) was present (median CD22 MFI ± SD was 5.90 ± 2.25 vs 10.20 ± 1.88 for patients with ILD vs healthy controls respectively; p = 0.011). CD22 phosphorylation following B cell receptor (BCR) stimulation was also found to be impaired in patients with diffuse SSc (median change in MFI ± SD was 0.28 ± 0.09 vs 0.38 ± 0.08 for patients vs healthy controls respectively; p = 0.034). Low CD22 expression was arithmetically correlated with kinase Lyn underexpression (Pearson coefficient 0.926; p = ns) in B cells from a small sample of patients. These results suggest that CD22 underexpression and impaired phosphorylation along with implications for Lyn kinase aberrations could contribute to the activated B cell phenotype in SSc.
Literature
1.
2.
3.
Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y et al (2002) CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 109:1453–1462CrossRefPubMedPubMedCentral
4.
Asano N, Fujimoto M, Yazawa N, Shirasawa S, Hasegawa M, Okochi H et al (2004) B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol 165:641–650CrossRefPubMedPubMedCentral
5.
Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E et al (2008) CD19 regulates skin and lung fibrosis via toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 172:1650–1663CrossRefPubMedPubMedCentral
6.
Komura K, Yanaba K, Horikawa M, Ogawa F, Fujimoto M, Tedder TF et al (2008) CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum 58:3574–3584CrossRefPubMed
7.
8.
Sato S, Fujimoto M, Hasegawa M, Takehara K (2004) Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum 50:1918–1927CrossRefPubMed
9.
Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S (2006) Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54:192–201CrossRefPubMed
10.
Mavropoulos A, Simopoulou T, Varna A, Liaskos C, Katsiari CG, Bogdanos DP et al (2016) Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis. Arthritis Rheumatol 68:494–504CrossRefPubMed
11.
Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K, Fujimoto M (2016) Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity. Rheumatology 55:263–267CrossRefPubMed
12.
François A, Chatelus E, Wachsmann D, Sibilia J, Bahram S, Alsaleh G et al (2013) B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res Ther 15:R168CrossRefPubMedPubMedCentral
13.
14.
Dumoitier N, Chaigne B, Régent A, Lofek S, Mhibik M, Dorfmüller P et al (2017) Scleroderma peripheral B lymphocytes secrete interleukin-6 and transforming growth factor β and activate fibroblasts. Arthritis Rheumatol 69:1078–1089CrossRefPubMed
15.
Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi J-T, Pergamenschikov A et al (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 100:12319–12324CrossRefPubMedPubMedCentral
16.
Lafyatis R, O’Hara C, Feghali-Bostwick CA, Matteson E (2007) B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 56:3167–3168CrossRefPubMed
17.
De Santis M, Bosello SL, Peluso G, Pinnelli M, Alivernini S, Zizzo G et al (2012) Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. Clin Respir J 6:9–17CrossRefPubMed
18.
Rueda B, Gourh P, Broen J, Agarwal SK, Simeon C, Ortego-Centeno N et al (2010) BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians. Ann Rheum Dis 69:700–705CrossRefPubMed
19.
Ito I, Kawaguchi Y, Kawasaki A, Hasegawa M, Ohashi J, Kawamoto M et al (2010) Association of the FAM167A-BLK region with systemic sclerosis. Arthritis Rheum 62:890–895CrossRefPubMed
20.
Tedder TF, Sato S, Poe JC, Fujimoto M (2000) CD19 and CD22 regulate a B lymphocyte signal transduction pathway that contributes to autoimmunity. Keio J Med 49:1–13CrossRefPubMed
21.
Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K (2000) Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165:6635–6643CrossRefPubMed
22.
Müller J, Nitschke L (2014) The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease. Nat Rev Rheumatol 10:422–428CrossRefPubMed
23.
Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J (2004) B cell antigen receptor signaling 101. Mol Immunol 41:599–613CrossRefPubMed
24.
25.
Gross AJ, Lyandres JR, Panigrahi AK, Prak ETL, DeFranco AL (2009) Developmental acquisition of the Lyn-CD22-SHP-1 inhibitory pathway promotes B cell tolerance. J Immunol 182:5382–5392CrossRefPubMedPubMedCentral
26.
Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative: ACR/EULAR classification criteria for SSc. Arthritis Rheum 65:2737–2747CrossRefPubMedPubMedCentral
27.
Karampetsou MP, Andonopoulos AP, Liossis S-NC (2011) Treatment with TNFα blockers induces phenotypical and functional aberrations in peripheral B cells. Clin Immunol 140:8–17CrossRefPubMed
28.
Doody GM, Justement LB, Delibrias CC, Matthews RJ, Lin J, Thomas ML et al (1995) A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science 269:242–244CrossRefPubMed
29.
O’Keefe TL, Williams GT, Batista FD, Neuberger MS (1999) Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 189:1307–1313CrossRefPubMedPubMedCentral
30.
Soto L, Ferrier A, Aravena O, Fonseca E, Berendsen J, Biere A et al (2015) Systemic sclerosis patients present alterations in the expression of molecules involved in B-cell regulation. Front Immunol 6:496CrossRefPubMedPubMedCentral
31.
Hitomi Y, Tsuchiya N, Hasegawa M, Fujimoto M, Takehara K, Tokunaga K et al (2007) Association of CD22 gene polymorphism with susceptibility to limited cutaneous systemic sclerosis. Tissue Antigens 69:242–249CrossRefPubMed
32.
Odaka M, Hasegawa M, Hamaguchi Y, Ishiura N, Kumada S, Matsushita T et al (2010) Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis. Clin Exp Immunol 159:176–184CrossRefPubMedPubMedCentral
33.
Liossis SN, Solomou EE, Dimopoulos MA, Panayiotidis P, Mavrikakis MM, Sfikakis PP (2001) B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. J Investig Med 49:157–165CrossRefPubMed
34.
Clowse MEB, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P et al (2017) Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol 69:362–375CrossRefPubMedPubMedCentral
35.
Lumb S, Fleischer SJ, Wiedemann A, Daridon C, Maloney A, Shock A et al (2016) Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor. J Cell Commun Signal 10:143–151CrossRefPubMedPubMedCentral
36.
Sieger N, Fleischer SJ, Mei HE, Reiter K, Shock A, Burmester GR et al (2013) CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation. Arthritis Rheum 65:770–779CrossRefPubMed
37.
Giltiay NV, Shu GL, Shock A, Clark EA (2017) Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling. Arthritis Res Ther 19:91CrossRefPubMedPubMedCentral
38.
McGonagle D, Tan AL, Madden J, Rawstron AC, Rehman A, Emery P et al (2008) Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology 47:552–553CrossRefPubMed
39.
Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ et al (2009) B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 60:578–583CrossRefPubMedPubMedCentral
40.
Daoussis D, Liossis S-NC, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C et al (2010) Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 49:271–280CrossRefPubMed
41.
Bosello S, De Santis M, Lama G, Spanò C, Angelucci C, Tolusso B et al (2010) B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 12:R54CrossRefPubMedPubMedCentral
42.
Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S et al (2010) Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 69:193–197CrossRefPubMed
43.
Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M et al (2014) Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 19:353–359CrossRefPubMed
44.
Jordan S, Distler JHW, Maurer B, Huscher D, Laar JM van, Allanore Y et al (2015) Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 74:1188–1194CrossRefPubMed
45.
Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T et al (2017) A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 46:625–631CrossRefPubMed
Metadata
Title
Decreased CD22 expression and intracellular signaling aberrations in B cells of patients with systemic sclerosis
Authors
Konstantinos Melissaropoulos
Stamatis-Nick Liossis
Publication date
01-07-2018
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 7/2018
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-018-4076-3

Other articles of this Issue 7/2018

Rheumatology International 7/2018 Go to the issue

Patient Opinion

English-language videos on YouTube as a source of information on self-administer subcutaneous anti-tumour necrosis factor agent injections

Cases with a Message

Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn’s disease-associated spondyloarthropathy

Cases with a Message

Improvement of neurological and ocular symptoms of Behçet’s disease after the introduction of infliximab

Cases with a Message

Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review

Observational Research

Serum profile of transferrin isoforms in juvenile idiopathic arthritis: a preliminary study

Correspondence

Carpal tunnel syndrome treatment with palmitoylethanolamide: neurophysiology and ultrasound show small changes in the median nerve
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits